An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

722

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: Dolutegravir (DTG)
DRUG: Lamivudine (3TC)
DRUG: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

Sponsor

ViiV Healthcare

Collaborators

[object Object]